CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Patient-tailored antithrombotic therapy following percutaneous coronary intervention A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD: The ASET Pilot Study State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation – past, present and future perspectives Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial

Review Article2021 Jan 29;ehaa1097.

JOURNAL:Eur Heart J. Article Link

Patient-tailored antithrombotic therapy following percutaneous coronary intervention

NMR van der Sangen, R Rozemeijer, DRPP CP Yin et al. Keywords: DAPT; patient-tailored antithrombotic therapy; risk stratification

Full Text PDF